A recent discussion in Mumbai on trends in the pharmaceutical and healthcare sector especially from the mergers and acquisitions (M&A) and funding perspective highlighted the appetite of large Indian companies for snapping up firms with niche portfolios in regulated markets like the US. Private equity firms at the end of their investment cycles and heightened FDA inspection activity in India are also expected to trigger more transactions.
Rikin Sanghvi, senior vice president and head of pharma investment banking at ICICI Securities noted how large Indian players "flush...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?